Century Therapeutics (IPSC) Amortization of Deferred Charges (2020 - 2023)

Century Therapeutics (IPSC) has 4 years of Amortization of Deferred Charges data on file, last reported at $38000.0 in Q2 2023.

• Amortization of Deferred Charges for Q2 2023 came in at $38000.0, down 50.0% year-over-year; the trailing twelve-month figure through Dec 2023 was $94000.0 (down 68.46% YoY), and the FY2023 annual result was $94000.0, down 68.56% from the prior year.
• Amortization of Deferred Charges slipped to $38000.0 in Q2 2023 per IPSC's latest filing, from $56000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $78000.0 in Q4 2020 and troughed at $14000.0 in Q3 2020.
• A 4-year average of $65750.0 and a median of $76000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2021 and 2023: Amortization of Deferred Charges surged 450.0% in 2021, then plunged 50.0% in 2023.
• A 4-year view of Amortization of Deferred Charges shows it stood at $78000.0 in 2020, then declined by 1.28% to $77000.0 in 2021, then declined by 10.39% to $69000.0 in 2022, then slumped by 44.93% to $38000.0 in 2023.
• Business Quant data shows IPSC's Amortization of Deferred Charges at $38000.0 in Q2 2023, $56000.0 in Q1 2023, and $69000.0 in Q4 2022.